2030 Leads Side effects 
European Pharmaceutical Review
OCTOBER 7, 2022
billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes. This is especially beneficial as a way of decreasing potential side effects.
Pharmaceutical Technology
DECEMBER 16, 2022
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 26, 2022
This guidance is in line with the WHO’s End TB Strategy, which aims for an 80% fall in worldwide TB incidence and a 90% decrease in TB deaths by 2030, compared with 2015. As patients with a drug-resistant form of TB cannot receive the standard regimen, their treatment courses tend to be more complex and often cause unsavoury side effects.
pharmaphorum
SEPTEMBER 16, 2022
“Telemedicine is the leading decentralisation approach in clinical trials today and one that can help us to improve how we study the effects of our medicines on patients,” commented Stefan König, chief executive of George Medicines. By 2030, it is projected that over 215 million Africans will have hypertension.
European Pharmaceutical Review
MARCH 24, 2023
In NASH, excess fat in the liver can lead to progressive disease, including inflammation, liver cell injury and fibrosis, which are associated with increased risk for cardiovascular disease and liver morbidity and mortality. Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) side effects.
Medico Reach
FEBRUARY 8, 2023
from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. AI can lead to faster research, combining and extracting data into usable formats, making clinical trials more efficient and saving time. from 2023 to 2030. Poised to grow at a CAGR of 29.4% billion in 2022 and will expand at a CAGR of 10.3%
Celeritas
MARCH 3, 2023
Because drugs aren’t personalized, they often have irregular side effects. By 2030 it is predicted to rise by as much as 20% annually and most of this protein is sourced from the ocean. The issue is that results aren’t always predictable and outside variables could lead to a lack of conclusiveness.
Expert insights. Personalized for you.
98 
Let's personalize your content